Open AccessPatient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?
Author(s) -
Gabriel Horta-Baas
Publication year - 2022
Publication title -
patient related outcome measures
Language(s) - English
Resource type - Journals
ISSN - 1179-271X
DOI - 10.2147/prom.s256715
Subject(s) - biosimilar , medicine , discontinuation , cinahl , nocebo effect , adverse effect , medline , quality of life (healthcare) , inclusion (mineral) , clinical trial , rheumatoid arthritis , randomized controlled trial , alternative medicine , intensive care medicine , family medicine , physical therapy , placebo , psychological intervention , pathology , psychiatry , nursing , gender studies , sociology , political science , law
This review aims to provide an overview of the impact of TNFis biosimilars, with marketing authorization, in patient-reported outcome measures (PROMs) scores and explore how PROMs endpoints might add value in biosimilars uptake in RA patients.